Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
D'Huyvetter M, Vincke C, Xavier C, Aerts A, Impens N, Baatout S, De Raeve H, Muyldermans S, Caveliers V, Devoogdt N, Lahoutte T.
D'Huyvetter M, et al. Among authors: vincke c.
Theranostics. 2014 Apr 25;4(7):708-20. doi: 10.7150/thno.8156. eCollection 2014.
Theranostics. 2014.
PMID: 24883121
Free PMC article.